A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2017
At a glance
- Drugs SR T100 (Primary)
- Indications Warts
- Focus Therapeutic Use
- Sponsors G&E Herbal Biotechnology
- 27 Nov 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 27 Nov 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 27 Nov 2017 Status changed from withdrawn prior to enrolment to not yet recruiting.